iBio, Inc.
NASDAQ:IBIOBiotechnology
+$0.00 today
- Market cap
- $59.75M
- Beta
- 1.29
- P/E (TTM)
- -3.6
- EPS (TTM)
- -$0.32
Volume 0.84M
Average 0.81M
IBIO Debt Repayment
Cash used to repay borrowings during the period.
iBio, Inc.NASDAQ: IBIO
Debt Repayment · Q4 FY2026 · quarter ended Jun 2026
Debt repayment growth accelerates
Q4 FY2026 debt repayment of $5.86M (cash outflow) rose 3102.2% year over year, ahead of the +854.5% change in trailing-twelve-month debt repayment. Over 3 fiscal years it compounded at -10.1% a year.
Context
- Debt repayment amounted to 6634.0% of revenue in FY2026, up 6441.3 pp from a year earlier.
- Debt repayment grew in size in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +3102.2% holds above the trailing-twelve-month pace of +854.5%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Debt Repayment history
USD · from the cash flow
- Latest · FY2026
- (6.63M) USD
- Year-over-year change
- -760.4%
| Period | Period end | Debt Repayment | YoY change |
|---|---|---|---|
| FY2026 | 2026-06-30 | (6.63M) | -760.4% |
| FY2025 | 2025-06-30 | (771K) | +32.2% |
| FY2024 | 2024-06-30 | (1.14M) | +87.5% |
| FY2023 | 2023-06-30 | (9.13M) | -56.5% |
| FY2022 | 2022-06-30 | (5.83M) | — |
Debt Repayment vs competitors
How IBIO compares with its peers on the latest reported figures
- IBIO's LTM Jun 2026 debt repayment of $6.63M is the largest of the 4 companies compared; the peer median is $0.
- Debt repayment amounts to 6634.0% of revenue for IBIO, versus a peer median of 0.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $6.63M | +854.5% | -10.1% | 6634.0% | |
| LTM Mar 2026 | $0 | — | — | — | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | — | |
| Peer median (excluding IBIO) | $0 | — | — | 0.0% | |
Competitors are the stored peer set for IBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2022 Jun 2022 | FY2023 Jun 2023 | FY2024 Jun 2024 | FY2025 Jun 2025 | FY2026 Jun 2026 |
|---|---|---|---|---|---|
| Net Income | (29.51M) | (65.01M) | (24.91M) | (18.38M) | (33.04M) |
| Depreciation & Amortization | 3.79M | 1.38M | 1.25M | 291K | 88K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 4.38M | 4.39M | 2.04M | 1.53M | 1.37M |
| Change in Working Capital | 3.24M | 5.87M | (3.17M) | 479K | 2.52M |
| Accounts Receivables | 4.21M | 6.1M | 0 | 0 | (65K) |
| Inventory | (3.87M) | (1.02M) | 0 | 0 | 0 |
| Accounts Payables | 1.24M | (625K) | (1.49M) | 1.83M | 2.22M |
| Other Working Capital | 1.66M | 1.41M | (1.68M) | (1.35M) | 364K |
| Other Non-Cash Items | (15.32M) | 22.93M | 6.23M | 773K | 5.84M |
| Operating Cash Flow | (37.8M) | (30.44M) | (18.55M) | (15.3M) | (23.22M) |
| Capital Expenditures | (7.33M) | (5.74M) | (210K) | (16K) | (578K) |
| Acquisitions (Net) | 0 | (692K) | 0 | 0 | 0 |
| Purchases of Investments | (7.12M) | 0 | 0 | 0 | (42.3M) |
| Sales of Investments | 13.62M | 10.84M | 0 | 0 | 0 |
| Other Investing Activities | (4.3M) | 2.6M | 1.12M | 758K | 10.88M |
| Investing Cash Flow | (5.13M) | 7.01M | 906K | 742K | (32M) |
| Debt Repayment | (5.83M) | (9.13M) | (1.14M) | (771K) | (6.63M) |
| Common Stock Issued | 77K | 11.49M | 25.52M | 9.7M | 109.58M |
| Common Stock Repurchased | 0 | (39K) | (7K) | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (50K) | (22K) | 197K | 0 | 105K |
| Financing Cash Flow | (5.8M) | 2.3M | 24.49M | 8.93M | 103.05M |
| Effect of Forex Changes | (6M) | 33K | 0 | 0 | (18K) |
| Net Change in Cash | (54.73M) | (21.09M) | 6.85M | (5.63M) | 47.83M |
| Free Cash Flow | (45.13M) | (36.17M) | (18.76M) | (15.32M) | (23.8M) |
iBio, Inc.
NASDAQ:IBIO
Intrinsic Alpha fair value
Locked
Current Price
$0.85
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.